These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2116583)

  • 41. Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada.
    Ten Haaf K; Tammemägi MC; Bondy SJ; van der Aalst CM; Gu S; McGregor SE; Nicholas G; de Koning HJ; Paszat LF
    PLoS Med; 2017 Feb; 14(2):e1002225. PubMed ID: 28170394
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania.
    Gilson L; Mkanje R; Grosskurth H; Mosha F; Picard J; Gavyole A; Todd J; Mayaud P; Swai R; Fransen L; Mabey D; Mills A; Hayes R
    Lancet; 1997 Dec 20-27; 350(9094):1805-9. PubMed ID: 9428251
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients.
    Milne RJ; Vander Hoorn S; Jackson RT
    Pharmacoeconomics; 1997 Sep; 12(3):384-408. PubMed ID: 10170463
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiovascular disease.
    Hoare J
    Health Serv Manage; 1992 Oct; 88(7):19, 21. PubMed ID: 10122090
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The cost-effectiveness of forty health interventions in Guinea.
    Jha P; Bangoura O; Ranson K
    Health Policy Plan; 1998 Sep; 13(3):249-62. PubMed ID: 10187595
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.
    Grover SA; Coupal L; Paquet S; Zowall H
    Arch Intern Med; 1999 Mar; 159(6):593-600. PubMed ID: 10090116
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness analysis of a quality-controlled mammography screening program from the Swiss statutory health-care perspective: quantitative assessment of the most influential factors.
    Neeser K; Szucs T; Bulliard JL; Bachmann G; Schramm W
    Value Health; 2007; 10(1):42-53. PubMed ID: 17261115
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A new methodology for cost-effectiveness studies of domestic radon remediation programmes: quality-adjusted life-years gained within primary care trusts in central England.
    Coskeran T; Denman A; Phillips P; Gillmore G; Tornberg R
    Sci Total Environ; 2006 Jul; 366(1):32-46. PubMed ID: 16574198
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Economic Impact of Smoking and of Reducing Smoking Prevalence: Review of Evidence.
    Ekpu VU; Brown AK
    Tob Use Insights; 2015; 8():1-35. PubMed ID: 26242225
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D; Park HJ; Ko SK
    Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Priorities among recommended clinical preventive services.
    Coffield AB; Maciosek MV; McGinnis JM; Harris JR; Caldwell MB; Teutsch SM; Atkins D; Richland JH; Haddix A
    Am J Prev Med; 2001 Jul; 21(1):1-9. PubMed ID: 11418251
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study.
    Briggs A; Mihaylova B; Sculpher M; Hall A; Wolstenholme J; Simoons M; Deckers J; Ferrari R; Remme WJ; Bertrand M; Fox K;
    Heart; 2007 Sep; 93(9):1081-6. PubMed ID: 17135223
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
    Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
    Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A systematic review of economic evaluations of screening programmes for cardiometabolic diseases.
    Hiligsmann M; Wyers CE; Mayer S; Evers SM; Ruwaard D
    Eur J Public Health; 2017 Aug; 27(4):621-631. PubMed ID: 28040737
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Economic evaluations on cardiovascular preventive interventions in Argentina.
    Colantonio LD; Martí SG; Rubinstein AL
    Expert Rev Pharmacoecon Outcomes Res; 2010 Aug; 10(4):465-73. PubMed ID: 20715922
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness of motivational interviewing for smoking cessation and relapse prevention among low-income pregnant women: a randomized controlled trial.
    Ruger JP; Weinstein MC; Hammond SK; Kearney MH; Emmons KM
    Value Health; 2008; 11(2):191-8. PubMed ID: 17854434
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluating the potential cost-effectiveness of stenting as a treatment for symptomatic single-vessel coronary disease. Use of a decision-analytic model.
    Cohen DJ; Breall JA; Ho KK; Kuntz RE; Goldman L; Baim DS; Weinstein MC
    Circulation; 1994 Apr; 89(4):1859-74. PubMed ID: 8149551
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis.
    Mahadevia PJ; Fleisher LA; Frick KD; Eng J; Goodman SN; Powe NR
    JAMA; 2003 Jan; 289(3):313-22. PubMed ID: 12525232
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis.
    Karnon J; Peters J; Platt J; Chilcott J; McGoogan E; Brewer N
    Health Technol Assess; 2004 May; 8(20):iii, 1-78. PubMed ID: 15147611
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.